Please assess the completion status of the following clinical trial:

Trial Title: Study of Anti-Viral Prophylaxis for HBsAg(+) or HBcAb(+)/HBsAb(-) Patients Starting Anti-TNFα

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic hepatitis B, inactive HBsAg carriers or anti-HBc antibody positive patients with AST, ALT level equal or lower than 2x ULN~* Patient who has systemic rheumatic disease for which anti-TNFα treatment indication has been approved by the KFDA; rheumatoid arthritis (RA, 1987 ACR criteria), ankylosing spondylitis (AS, modified New York criteria), psoriatic arthritis (PsA, modified ESSG criteria), and juvenile rheumatoid arthritis (JRA, 1977 ACR criteria).~* Patient who is eligible to start anti-TNFα treatment (etanercept, infliximab, adalimumab, golimumab, and certolizumab pegol) due to treatment failure of other DMARDs against underlying RA, AS, PsA, or JRA. Patient who also fully understands that anti-TNFα agent expenses are not covered in this study.~* Patient who is willing and able to comply with the study drug regimen and all other study requirements~* Patient who is willing and able to provide a written informed consent to participate in the study~Exclusion Criteria:~* Patient who has liver cirrhosis or a history of hepatocellular carcinoma (HCC) or findings suggestive of HCC, such as suspicious foci or elevated serum alpha fetoprotein (AFP)~* Patient who received interferon or other immunomodulatory treatment for HBV infection in the 12 months before screening for this study~* Patient who has concomitant other chronic viral infection (HCV or HIV)~* Patient who is pregnant or breastfeeding or willing to be pregnant~* A history of chronic infection, recent serious or life-threatening infection. Especially,~  * Patient with current clinical or laboratory evidence of active tuberculosis (TB) or latent TB unless there is documentation of prior anti-TB treatment was appropriate in duration according to the Korea Food and Drug Administration (KFDA) guidelines for management of latent TB in patients being treated with biologic agents~ * Patient with a history of herpes zoster within 2 months before screening for this study~* Active malignancy or a history of treated malignancy less than 5 years prior to screening~* Patients who are not cooperative or unable to comply with the study procedures~* Patients with any other condition which the investigator's judgment would make the patient unsuitable for inclusion in the study such as alcohol and drug abuse

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Experimental Group (Type: EXPERIMENTAL): Entecavir (Baraclude (Bristol-Myers Squibb) 0.5mg.) will be taken orally on an empty stomach (2 hours after a meal or at least 2 hours before the next meal), once daily from 1 week before starting anti-TNFα and continue 72 weeks after anti-TNFα is administered.
- Control Group (Type: PLACEBO_COMPARATOR): Placebo of Entecavir (prepared by Bristol-Myers Squibb) will be taken orally on an empty stomach (2 hours after a meal or at least 2 hours before the next meal), once daily from 1 week before starting anti-TNFα and continue 72 weeks after anti-TNFα is administered.

Based on this trial design, predict the completion outcome and termination type (if applicable).